Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, glibenclamide (Amglidia®) cannot be endorsed for use within NHS Wales for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. |
||
|
||
Medicine details |
||
| Medicine name | glibenclamide (Amglidia®) | |
| Formulation | 0.6 mg/ml and 6 mg/ml oral suspension | |
| Reference number | 3733 | |
| Indication | Treatment of neonatal diabetes mellitus, for use in newborns, infants and children. |
|
| Company | Amring Pharmaceuticals | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 19/12/2018 | |